These are last month’s pharma news and developments brought to you by Congress Bookers, a reliable accommodation partner for lead pharma companies worldwide.
Amgen signs collaboration agreement with Array BioPharma
Amgen and Array BioPharma announced a preclinical license and collaboration agreement in inflammation.
Under the agreement, the two companies will collaborate on the discovery and development of new drugs for autoimmune disorders. Amgen will be responsible for clinical development and commercialization, having exclusive rights to Array’s preclinical program. In turn, upfront and milestone payments will be made by Amgen.
Bavarian Nordic partnered with Johnson & Johnson for HIV, HBV shots
Danish company Bavarian Nordic and Johnson & Johnson have signed a deal worth USD 879M to develop HIV, HBV shots.
Under the terms of the deal, Bavarian Nordic is granting J&J’s Janssen unit the rights to combine MVA-BN with Janssen’s own AdVac platform in the HIV and HBV programs. In return, Janssen will pay Bavarian Nordic $10 million upfront and up to $836 million in milestones. Bavarian Nordic will design, produce and deliver the MVA needed, while Janssen will handle R&D.
Samsung and Merck launched Remicade biosim
Samsung and Merck & Co. launched Renflexis in the US. Renflexis is 35% cheaper than J&J’s anti-inflammatory med.
Last year, Pfizer launched its version, Inflectra, at a 15% discount. Renflexis is the third biosim to launch in the US after Inflectra and Sandoz’s Zarxio, a biosimilar to Amgen’s Neupogen.
Gilead’s Vosevi got US FDA Approval
The US Food and Drug Administration (FDA) has approved Gilead Sciences’ Vosevi tablets, a single-tablet regimen for the re-treatment of chronic hepatitis C virus (HCV) infection in adults with genotype 1, 2, 3, 4, 5 or 6 previously treated with an NS5A inhibitor-containing regimen, or with genotype 1a or 3 previously treated with a sofosbuvir-containing regimen without an NS5A inhibitor.
The approval is based on data from the Phase 3 POLARIS-1 and POLARIS-4 studies, which evaluated Vosevi during an interval of 12 weeks.
Novo Nordisk and Glooko launch co-marketed app
As a result of Novo Nordisk’s partnership with diabetes health tech startup Glooko a new app was launched. It’s dubbed Cornerstones4Care Powered by Glooko, or the C4C app.
The app allows diabetes patients to measure and track blood glucose, activities and meals. It syncs blood glucose and activity data from a wide array of diabetes or exercise devices.
The app is free for registered C4C online users and can be downloaded from the Apple or Google app stores.
AstraZeneca partners with Merck to develop and commercialise cancer drugs
AstraZeneca and Merck & Co have entered a global oncology collaboration to co-develop and co-commercialise the AstraZeneca’s Lynparza and selumetinib for various cancer types.
Under the agreement, the companies will develop and commercialise Lynparza jointly, as monotherapy and in combination with other potential medicines. Furthermore, they will develop and commercialise Lynparza in combination with their own PD-L1 and PD-1 medicines, Imfinzi and Keytruda.
AstraZeneca and Merck will also co-develop and commercialise selumetinib, the former’s selective inhibitor of MEK, that’s being developed for several indications including thyroid cancer.
The 2 companies will share development and commercialisation costs as well as profits from product sales.
Congress Bookers provides a whole range of services needed to organize a group for a medical congress. On our website, you will find a full list of hotel allotments for the most important medical congresses in 2017 and 2018, regardless of their location. The biggest congresses next year are:
- EASL 2018 – 210 rooms in seven 4-star hotels
- EAACI 2018 – 615 rooms in fourteen 4-star hotels
- EHA 2018 – 1200 rooms in thirty 4-star hotels
- ERS 2018 – 615 rooms in twenty 4-star hotels
- EURETINA 2018 – 460 rooms in twelve 4-star hotels
- EASD 2018 – 765 rooms in sixteen 4-star hotels
- ECTRIMS 2018 – 620 rooms in ten hotels
- ESMO 2018 – 1092 rooms in twenty-one 4-star hotels.